Personalized Oral Cancer Vaccines: How Oral Surgeon R. Bryan Bell, MD, DDS, and Cancer Researchers Are Shaping the Future of Treatment
For decades, cancer vaccines seemed to live permanently five years in the future. That changed in 2026. Merck and Moderna reported that their personalized mRNA cancer vaccine, intismeran autogene, reduced the relative risk of melanoma recurrence or death by 42% when added to pembrolizumab, better known as Keytruda, in a randomized Phase 3 trial involving 1,137 patients. At two years, 82.2% of patients receiving the personalized vaccine plus Keytruda remained recurrence free, compared with 70% receiving Keytruda alone. The combination also reduced the risk of distant metastasis or death by 38%. Overall survival data remain immature, but personalized cancer vaccination has moved from an intriguing immunology experiment into late stage clinical oncology.
The idea is straightforward to describe and remarkably difficult to execute. A patient’s tumor and normal blood are sequenced. Scientists identify mutations found in the cancer but not in healthy tissue, then use algorithms to rank which altered proteins are most likely to be recognized by that patient’s immune system. Moderna’s platform can encode as many as 34 selected neoantigens into a patient specific mRNA product. The finished treatment is manufactured for that individual patient and returned for a series of injections, usually alongside pembrolizumab. The vaccine trains T cells to recognize the patient’s cancer, while Keytruda blocks one of the molecular signals tumors use to suppress that immune response.
For dentists, the more immediate question is whether the same strategy can work against oral and head and neck cancer. TG4050, developed by Transgene, takes a different technological route. Rather than using mRNA, it packages selected patient specific neoantigens into a modified vaccinia Ankara viral vector. In its randomized Phase 1 head and neck cancer trial, 24 of 33 patients, nearly 73%, had cancers originating in the oral cavity. These patients had already undergone surgery followed by radiation, with or without cisplatin, and had no detectable cancer when they entered the study. Seventeen were assigned to receive TG4050 immediately, while 16 were observed and could receive the vaccine if their cancer returned.
The early result deserves attention. Among 16 evaluable patients who received TG4050 immediately, none developed a recurrence during the initial follow up period, compared with three recurrences among 16 patients in the observation group. The vaccine also produced measurable neoantigen specific T cell responses in 11 of 15 evaluable patients, or 73.3%. Some immune responses appeared within two weeks, and in strong responders they remained detectable for as long as two years. No vaccine related grade 3 or higher adverse events were reported.
Those numbers are encouraging, but they should not be mistaken for proof. Phase 1 trials are primarily designed to establish safety and feasibility. Sixteen patients versus 16 patients is far too small a comparison to establish that TG4050 prevents oral cancer recurrence. Zero recurrences versus three is an intriguing signal that justifies a larger trial.
That distinction becomes especially important when patients encounter the word cure. TG4050 did not take patients with large untreated oral cancers and make those tumors disappear. These patients had already received potentially curative surgery and adjuvant therapy and were clinically disease free when vaccination began. The question was whether the vaccine could help the immune system recognize and eliminate microscopic residual cancer before it developed into a recurrence.
That may ultimately prove to be the best setting for this technology. Asking the immune system to eliminate a small number of residual malignant cells is a very different challenge from overcoming a large metastatic tumor with an established immunosuppressive environment. Personalized cancer vaccines may therefore prove most useful in preventing recurrence after successful surgery.
The TG4050 program has now expanded into an 80 patient Phase 1/2 trial that includes stage III and IV squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx. The study is active but no longer recruiting. Disease free survival is now a primary outcome, and the larger cohort should provide a much better indication of whether the early recurrence signal can be reproduced. If it can, personalized vaccination could eventually become another postoperative tool in selected patients with high risk oral and head and neck cancer.
There are reasons to remain disciplined. Personalized cancer vaccines will not necessarily work equally well across tumor types. BioNTech and Genentech halted a Phase 2 personalized vaccine study in colorectal cancer after an independent review determined that the trial was unlikely to demonstrate efficacy. Melanoma is highly immunogenic and often carries many mutations capable of producing recognizable neoantigens. Other cancers may offer fewer useful targets or create tumor environments that are harder for activated T cells to penetrate. Oral squamous cell carcinoma will have to prove itself on its own clinical evidence.
Dentistry already has a remarkable connection to this developing field through R. Bryan Bell, MD, DDS, an oral and maxillofacial surgeon and head and neck cancer surgeon at Providence Cancer Institute in Oregon. Bell has spent much of his career working at the intersection of surgery, immunotherapy, and translational cancer research. His work has explored how immune based therapies can be incorporated before and after surgery for oral and head and neck malignancies, while his institution has participated in the broader Moderna and Merck personalized vaccine research program.
Bell’s career illustrates how far oral and maxillofacial surgery has moved into modern cancer biology. Today’s head and neck cancer surgeon may remove a tumor, reconstruct the defect, study the tumor microenvironment, sequence malignant tissue, and help test therapies designed to activate the patient’s own immune system against whatever cancer cells remain. The boundary between surgery and systemic cancer therapy is becoming less distinct.
The logistical challenge behind these treatments is almost as interesting as the biology. Each patient requires matched tumor and blood samples, DNA and RNA sequencing, HLA typing, computational neoantigen prediction, individualized manufacturing, purification, quality control, chain of identity, cold storage, and delivery back to the correct patient. Moderna reports that its current clinical process takes approximately six weeks from receipt of adequate specimens to delivery of the finished product, with manufacturing success above 99% once usable neoantigens are identified.
This reverses the traditional pharmaceutical model. Drug companies normally manufacture millions of identical doses. Personalized cancer vaccines require thousands of different medicines, each intended for one person. The challenge is whether healthcare systems can manufacture them quickly, reliably, and economically enough to make the approach broadly available.
For the practicing dentist, none of this changes tomorrow morning’s oral cancer examination. Early recognition, biopsy, referral, surgery, radiation, chemotherapy, and established immunotherapies remain the foundation of oral cancer care. What will change sooner is the conversation with patients. Someone who reads about a personalized cancer vaccine may assume oral cancer can now be treated with a custom injection instead of conventional therapy. Dentists should be able to explain that personalized cancer vaccines are real, that the technology has now succeeded in a large Phase 3 melanoma trial, and that early head and neck cancer results are promising, while making clear that personalized vaccination remains investigational for oral squamous cell carcinoma.
Dentists may also have a growing role in directing patients toward legitimate clinical trials. When patients ask about experimental therapies, the safest path is through established academic cancer centers, multidisciplinary head and neck oncology programs, and registered clinical trials. Personalized medicine attracts serious science, but it also creates opportunities for clinics to market expensive treatments before convincing evidence exists. Patients need clinicians who can tell the difference.
The most intriguing possibility is what could happen to the pathology specimen after an oral cancer is removed. For more than a century, that tissue has primarily told us what the tumor was, how aggressive it appeared, whether margins were clear, and how far disease had spread. In the emerging model of personalized immunotherapy, the tumor could also become the blueprint for the patient’s next treatment. Its mutations may provide the instructions for manufacturing a vaccine designed to patrol for microscopic disease long after the surgeon has removed everything visible.
That future has not arrived in routine dental or oncology practice. For the first time, however, it is close enough to be tested in randomized human trials.
If a patient’s own oral cancer can someday provide the instructions for preventing its return, how will that change the dentist’s role in cancer care?
Join the Conversation!